Lviv clinical bulletin 2020, 4(32): 61-72

https://doi.org/10.25040/lkv2020.04.061

Vulvar Intraepithelial Neoplasia: Modern Views on the Problem, Management Methods (Literature Review); Own Clinical Expertise of Using the Photodynamic Method in Its Treatment

Posted onAuthorAdminЗалишити коментар / Leave a comment

V. Dunaevska, T. Tatarchuk, D. Tzerkovskyi

 

Introduction. Vulvar intraepithelial neoplasia is a precancerous pathology of the vulva and is a very important medical and social problem. All the efforts of medical science are aimed at finding and developing the latest organ-preserving methods for the treatment of vulvar intraepithelial neoplasia. One of them is photodynamic therapy-method that allows preserving the anatomical structure of the organ.

The aim of the study. The aim of the article is to carry out an analytical review of the literature on modern views on the problem of vulvar intraepithelial neoplasia, methods of its management and to present the results of the own clinical expertise of using a photodynamic method for its treatment.

Materials and methods. Content analysis, method of system and comparative analysis, bibliosemantic method of studying the results of current scientific research on modern views on the problem of vulvar intraepithelial neoplasia, methods of its management have been used in the article. Fifty-six literature sources in English have been studied and analyzed. The sources have been taken in the following scientometric medical databases: PubMed-NCBI, Medline, ResearchGate, CochraneLibrary, EMBASE by keywords: intraepithelial neoplasia of the vulva, vulvar intraepithelial neoplasia (VIN), photodynamic therapy (PDT), treatment of vulvar intraepithelial neoplasia; VIN treatment. The results of own clinical expertise of using the photodynamic method for vulvar intraepithelial neoplasia treatment have been described in the article as well.

Results. During the PS infusion and the period before the PDT session, the general condition of the patients was satisfactory, and the symptoms of cutaneous phototoxicity, allergic reactions, which were accompanied by severe dysfunctions of vital organs, were absent after it. Despite the premedication carried out before the PDT session, the patients had moderate pain syndrome (I-II degrees) after the session as well as moderately pronounced edema in the area of pathological tissues being under the influence of photoirradiation. Within 1-5 days after treatment, the beginning of the formation of a dark brown or black area of photochemical necrosis was noted. After 3, 6 and 24 months of observation of patients with precancerosis of the vulva, remission of clinical symptoms (pruritus in the vulva) in the treated pathological foci was stated. It should be noted that the insufficient effectiveness of PDT in five cases was due to the use of subtherapeutic doses of PS “Photolon®”. During the follow-up examination at 3, 6 and 24 months in 20 out of 30 patients who received a photosensibilizer session in a subtherapeutic dose followed by photoirradiation of high power (1.0 W), both clinically and morphologically complete regression was noted being justified from both treatment and financial point of view.

In the post-procedural period, all patients who were treated with PDT are recommended to: observe the light regime for 3-4 days; adequate pain relief use; hygiene; sexual rest; local treatment.

Conclusions. The real advantage of photodynamic therapy associated with vulvar intraepithelial neoplasia is its ability to treat the multifocal disease with minimal tissue destruction, preservation of the vulva anatomy and excellent cosmetic results. These properties confirm the photodynamic therapy to be an effective method in vulvar intraepithelial neoplasia treatment.

References

  1. Artemieva TP, Tserkovsky DA. Photodynamic therapy for vulvar leukoplakia. Biomedical Photonics. 2018;7(4):4-10.
  2. Abdel-Hady ES, Martin-Hirsch P, Duggan-Keen M, Stern PL, Moore JV, Corbitt G, Kitchener HC, Hampson N. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res. 2001;61:192-196.
  3. Ang JM, Riaz IB, Kamal MU, Paragh G, Zeitouni NC. Photodynamic therapy and pain: A systematic review. Photodiagn Photodyn Ther. 2017;19:308-344.
  4. Baandrup L, Varbo A, Munk C, Johansen C, Frisch M, Kjaer SK. In situ and invasive squamous cell carcinoma of the vulva in Denmark 1978–2007-a nationwide population-based study. Gynecol Oncol. 2011;122:45-49.
  5. Barisani A, Dika E, Fanti PA, De Iaco P, Tosti G, Patrizi A, Vaccari S. Dermoscopic findings of vulvar intraepithelial neoplasia: A series of four cases. Br J Dermatol. 2017;176:227-230.
  6. Bornstein J, Bogliatto F, Haefner HK, Stockdale CK, Preti M, Bohl TG, Reutter J. ISSVD Terminology Committee. The 2015 International Society for the Study of Vulvovaginal Disease (ISSVD) Terminology of Vulvar Squamous Intraepithelial Lesions. Obstet Gynecol. 2016;127:264-268.
  7. Campbell SM, Gould DJ, Salter L, Clifford T, Curnow A. Photodynamic therapy using metatetrahydroxyphenylchlorin (Foscan) for the treatment of vulval intraepithelial neoplasia. Br J Dermatol. 2004;151:1076-1080.
  8. Castle PE, Maza M. Prophylactic HPV vaccination: Past, present, and future. Epidemiol Infect. 2016;144:449-468.
  9. Choi MC, Kim MS, Lee GH, Jung SG, Park H, Joo WD, Lee C, Lee JH, Hwang YY, Kim SJ. Photodynamic therapy for premalignant lesions of the vulva and vagina: A long-term follow-up study. Lasers Surg Med. 2015.
  10. Committee on Gynecologic Practice of American College Obstetricians and Gynecologists. ACOG Committee Opinion No. 509: Management of vulvar intraepithelial neoplasia. Obstet Gynecol. 2011;118:1192-1194.
  11. Daayana S, Winters U, Stern PL, Kitchener HC. Clinical and immunological response to photodynamic therapy in the treatment of vulval intraepithelial neoplasia. Photochem Photobiol Sci. 2011;10:802-809.
  12. Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, McCalmont T, Nayar R, Palefsky JM, Stoler MH et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: Background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis. 2012;1:205-242.
  13. De Bie RP, van de Nieuwenhof HP, Bekkers RL, Melchers WJ, Siebers AG, Bulten J, Massuger LF, de Hullu JA. Patients with usual vulvar intraepithelial neoplasia-related vulvar cancer have an increased risk of cervical abnormalities. Br J Cancer. 2009;101:27-31.
  14. De Sanjosé S, Alemany L, Ordi J, Tous S, Alejo M, Bigby SM, Joura EA, Maldonado P, Laco J, Bravo IG. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer. 2013;49:3450-3461.
  15. Del Pino M, Rodriguez-Carunchio L, Ordi J. Pathways of vulvar intraepithelial neoplasia and squamous cell carcinoma. Histopathology. 2013;62:161-175.
  16. Fehr MK, Hornung R, Schwarz VA, Simeon R, Haller U. Wyss P. Photodynamic therapy of vulvar intraepithelial neoplasia III using topically applied 5-aminolevulinic acid. Gynecol Oncol. 2001;80:62-66.
  17. Fox H, Wells M. Recent advances in the pathology of the vulva. Histopathology. 2003;42:209-216.
  18. Frost GA, Halliday GM, Damian DL. Photodynamic therapy-induced immunosuppression in humans is prevented by reducing the rate of light delivery. J Investig Dermatol. 2011;131:962-968.
  19. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J. Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928-1943.
  20. Gul N, Ganesan R, Luesley DM. Characterizing T-cell response in low-grade and high-grade vulval intraepithelial neoplasia, study of CD3, CD4 and CD8 expressions. Gynecol Oncol. 2004;94:48-53.
  21. Hart WR. Vulvar intraepithelial neoplasia: Historical aspects and current status. Int J Gynecol Pathol. 2001;30.
  22. Hillemanns P, Untch M, Dannecker C, Baumgartner R, Stepp H, Diebold J, Weingandt H, Pröve F, Korell M. Photodynamic therapy of vulvar intraepithelial neoplasia using 5-aminolevulinic acid. Int J Cancer. 2000;85:649-653.
  23. Hoang LN, Park KJ, Soslow RA, Murali R. Squamous precursor lesions of the vulva: Current classification and diagnostic challenges. Pathology. 2016;48:291-302.
  24. Iavazzo C, Pitsouni E, Athanasiou S, Falagas ME. Imiquimod for treatment of vulvar and vaginal intraepithelial neoplasia. Int J Gynaecol Obstet. 2008;101:3-10.
  25. Jones RW, Rowan DM. Spontaneous regression of vulvar intraepithelial neoplasia 2–3. Obstet Gynecol. 2000;96:470-472.
  26. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361: 1838-1847.
  27. Kokka F, Singh N, Faruqi A, Gibbon K, Rosenthal AN. Is differentiated vulval intraepithelial neoplasia the precursor lesion of human papillomavirus-negative vulval squamous cell carcinoma? Int J Gynecol Cancer. 2011;21:1297-1305.
  28. Kurwa HA, Barlow RJ, Neill S. Single-episode photodynamic therapy and vulval intraepithelial neoplasia type III resistant to conventional therapy. Br J Dermatol. 2000;143:1040-1042.
  29. Mantovani F, Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene. 2001;20:7874-7887.
  30. Martin-Hirsch PL, Whitehurst C, Buckley CH, Moore JV, Kitchener HC. Photodynamic treatment for lower genital tract intraepithelial neoplasia. Lancet. 1998;351:1403.
  31. Meeuwis KA, van Rossum MM, van de Kerkhof PC, Hoitsma AJ, Massuger LF, de Hullu JA. Skin cancer and (pre)malignancies of the female genital tract in renal transplant recipients. Transpl Int. 2010;23:191-199.
  32. Monk BJ, Burger RA, Lin F, Parham G, Vasilev SA, Wilczynski SP. Prognostic significance of human papillomavirus DNA in vulvar carcinoma. Obstet Gynecol. 1995;85:709-715.
  33. Morton CA, McKenna KE, Rhodes LE. British Association of Dermatologists Therapy Guidelines and Audit Subcommittee and the British Photodermatology Group. Guidelines for topical photodynamic therapy: Update. Br J Dermatol. 2008;159:1245-1266.
  34. Mroz P, Hamblin MR. The immunosuppressive side of PDT. Photochem Photobiol Sci. 2011;10:751-758.
  35. Münger K, Basile JR, Duensing S, Eichten A, Gonzalez SL, Grace M, Zacny VL. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene. 2001;20:7888-7898.
  36. Pepas L, Kaushik S, Nordin A, Bryant A, Lawrie TA. Medical interventions for high-grade vulval intraepithelial neoplasia. Cochrane Database Syst Rev. 2015;18:CD007924.
  37. Preti M, Scurry J, Marchitelli CE, Micheletti L. Vulvar intraepithelial neoplasia. Best Pract Res Clin Obstet Gynaecol. 2014;28:1051-1062.
  38. Preti M, Van Seters M, Sideri M, Van Beurden M. Squamous vulvar intraepithelial neoplasia. Clin Obstet Gynecol. 2005;48:845-861.
  39. Sandberg C, Halldin CB, Ericson MB, Larkö O, Krogstad AL, Wennberg AM. Bioavailability of aminolaevulinic acid and methylaminolaevulinate in basal cell carcinomas: A perfusion study using microdialysis in vivo. Br J Dermatol. 2008;159:1170-1176.
  40. Santegoets LA, van Seters M, Heijmans-Antonissen C, Kleinjan A, van Beurden M, Ewing PC, Kühne LC, Beckmann I, Burger CW, Helmerhorst TJ. Reduced local immunity in HPV-related VIN: Expression of chemokines and involvement of immunocompetent cells. Int J Cancer. 2008;123:616-622.
  41. Santos M, Montagut C, Mellado B, García A, Ramón y Cajal S, Cardesa A, Puig-Tintoré LM, Ordi J. Immunohistochemical staining for p16 and p53 in premalignant and malignant epithelial lesions of the vulva. Int J Gynecol Pathol. 2004;23:206-214.
  42. Sideri M, Jones RW, Wilkinson EJ, Preti M, Heller DS, Scurry J, Haefner H, Neill S. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. J Reprod Med. 2005;50:807-810.
  43. Soergel P, Hillemanns P. Photodynamic therapy for intraepithelial neoplasia of the lower genital tract. Photodiagn Photodyn Ther. 2010;7:10-14.
  44. Sykes P, Smith N, McCormick P, Frizelle FA. High-grade vulval intraepithelial neoplasia (VIN 3): A retrospective analysis of patient characteristics, management, outcome and relationship to squamous cell carcinoma of the vulva 1989–1999. Aust. N. Z. J. Obstet Gynaecol. 2002;42:69-74.
  45. Terlou A, van Seters M, Ewing PC, Aaronson NK, Gundy CM, Heijmans-Antonissen C, Quint WG, Blok LJ, van Beurden M, Helmerhorst TJ. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow-up of a randomized clinical trial. Gynecol Oncol. 2011;121:157-162.
  46. Tristram A, Fiander A. Clinical responses to Cidofovir applied topically to women with high grade vulval intraepithelial neoplasia. Gynecol Oncol. 2005;99:652-655.
  47. Tristram A, Hurt CN, Madden T, Powell N, Man S, Hibbitts S, Dutton P, Jones S, Nordin AJ, Naik R. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT3VIN): A multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2014;15:1361-1368.
  48. Ueda Y, Enomoto T, Kimura T, Yoshino K, Fujita M, Kimura T. Two distinct pathways to development of squamous cell carcinoma of the vulva. J Skin Cancer. 2011, 2011.
  49. Vaccari S, Barisani A, Preti EP, Dika E, Fanti PA, Patrizi A, Tosti G. Dermoscopic features of pigmented vulvar intraepithelial neoplasia. Clin Exp Dermatol. 2018;43:63-65.
  50. Van de Nieuwenhof HP, van Kempen LC, de Hullu JA, Bekkers RL, Bulten J, Melchers WJ, Massuger LF. The etiologic role of HPV in vulvar squamous cell carcinoma fine tuned. Cancer Epidemiol. Biomarkers Prev. 2009;18:2061-2067.
  51. Van de Nieuwenhof HP, Bulten J, Hollema H, Dommerholt RG, Massuger LF, van der Zee AG, de Hullu JA, van Kempen LC. Differentiated vulvar intraepithelial neoplasia is often found in lesions, previously diagnosed as lichen sclerosus, which have progressed to vulvar squamous cell carcinoma. Mod Pathol. 2011;24:297-305.
  52. Van de Nieuwenhof HP, Massuger LF, van der Avoort IA, Bekkers RL, Casparie M, Abma W, van Kempen LC, de Hullu JA. Vulvar squamous cell carcinoma development after diagnosis of VIN increases with age. Eur J Cancer. 2009;45:851-856.
  53. Van de Nieuwenhof HP, van der Avoort IA, de Hullu JA. Review of squamous premalignant vulvar lesions. Crit Rev Oncol Hematol. 2008;68:131-156.
  54. Van Esch EM, Dam MC, Osse ME, Putter H, Trimbos BJ, Fleuren G, van der Burg SH, van Poelgeest MI. Clinical characteristics associated with development of recurrence and progression in usual-type vulvar intraepithelial neoplasia. Int J Gynecol Cancer. 2013;23:1476-1483.
  55. Winters U, Daayana S, Lear JT, Tomlinson AE, Elkord E, Stern PL, Kitchener HC. Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia. Clin Cancer Res. 2008;14:5292-5299.
  56. Zawislak A, Donnelly RF, McCluggage WG, Price JH, McClelland HR, Woolfson AD, Dobbs S, Maxwell P, McCarron PA. Clinical and immunohistochemical assessment of vulval intraepithelial neoplasia following photodynamic therapy using a novel bioadhesive patch-type system loaded with 5-aminolevulinic acid. Photodiagn Photodyn Ther. 2009;6:28-40.